FDA Marks 100 Years of Drug Manufacturing Oversight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Marks 100 Years of Drug Manufacturing Oversight
Efforts to ensure drug purity and safety continue to evolve and to challenge industry and regulatory officials.


Pharmaceutical Technology


A fast-expanding pharmaceutical industry also was attracting public attention because of high drug prices, fairly rudimentary clinical-research activities, and increasingly bold claims in drug labeling and advertising. Senator Estes Kefauver began to hold hearings in 1960 on proposals to strengthen FDA oversight, including new rules for monitoring manufacturing practices.

The bill was going nowhere, though, until the horrifying effects of thalidomide on newborns became known in 1962. FDA reviewer Frances Kelsey had qualms about the NDA for the product, and her hesitation made her a hero overnight. The narrowly avoided tragedy prompted Congress to adopt the Kefauver–Harris Amendments, which required drug manufacturers to prove that products are both safe and effective before marketing. The measure also formalized good manufacturing practices (GMPs), required adverse-event reporting, and called for sponsors of clinical trials to obtain informed consent from study participants.

These new requirements prompted a major expansion of FDA's Division of New Drugs, forming separate branches to evaluate NDAs and to monitor clinical trials, manufacturing controls, and adverse-reaction reports. The National Center for Drug Analysis opened in St. Louis in 1967 to conduct large-scale tests of drug products. The Bureau of Drugs became the Bureau of Drugs and Biologics in 1980 to coordinate agency oversight better, but the combination proved unwieldy and lasted only a few years (see sidebar, "Challenges for CDER").

Another major initiative was to assess the safety and efficacy of the vast number of drugs already on the market that never had been formally evaluated for efficacy. The resulting Drug Efficacy Study Implementation (DESI) review of some 3500 products lasted almost 20 years. In 1972, FDA launched a similar retrospective review of over-the-counter drugs that led to monographs on the safety and efficacy of some 1000 active ingredients.

AIDS revolution

The 1980s were a time of important social and biomedical change in the United States that entailed major consequences for FDA. The first reports of AIDS appeared in 1981, prompting coordinated efforts by FDA and researchers to develop and approve immunoassay tests. Azidothymidine (AZT), the first drug to treat AIDS, was approved by FDA in 1987, along with additional treatments for certain opportunistic infections.

In addition, demands from well-informed AIDS patient advocates for faster access to promising therapies spurred a general rethinking of FDA regulatory attitudes. The thalidomide crisis had fostered a cautious approach at the agency, but the AIDS epidemic engendered a less risk-averse attitude. FDA revised rules to expand access to experimental drugs for severely ill patients and to permit market approval of AIDS and cancer treatments based on preliminary clinical results.

The need for biomedical innovation also built support for an innovative program to encourage the development of treatments for rare diseases. Congress approved the Orphan Drug Act in 1983, which extends market exclusivity for drugs and medical products that treat diseases affecting less than 200,000 people in the United States and has led to the approval of nearly 300 drugs and biologics.

Generics spur competition

In 1984, Congress established the basis for the modern generic drug industry with the enactment of the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch–Waxman Act. The bill allowed FDA to approve abbreviated applications for identical versions of brand-name drugs on the basis of preclinical and clinical testing performed by the innovator firm. Early access to innovator research data allows generics companies to develop and test generics before patent expiration.

The trade-off for brand-name companies is as many as five years of additional patent protection for new medicines to make up for time lost while their products went through FDA's approval process, which often ran for two or three years at that time. Unfortunately, the legislation attracted some inexperienced operators to this fast-growing industry, leading to fraudulent activities and a subsequent enforcement crackdown.

Monitoring distribution. In addition to illegal generic-drug activities, policymakers were increasingly concerned about questionable drug distribution and marketing activities. Congress approved the Prescription Drug Marketing Act of 1988, which gave FDA added authority to prevent drug diversion and resale by requiring industry to establish systems for tracking drugs and product samples. Specific approaches for implementing the legislation have been hard to negotiate, however, and FDA is only now requiring some wholesalers to establish pedigree systems to thwart sales of adulterated and counterfeit products.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here